Collaborations & Alliances
Related Searches:
Filter by:
July 1, 2008
Genmab has reached a development milestone for ofatumumab (HuMax-CD20) under the terms of its collaboration with GlaxoSmithKline. The milestone triggers a $6 million payment to Genmab as a result of the first patient treated in the Phase II study of…
Read More »
June 27, 2008
Schering-Plough and Merck withdrew the NDA for the Claritin (loratadine)/Singulair (montelukast) combination tablet. The companies also terminated the their respiratory joint venture formed in May 2000. The FDA issued a not-approvable letter in April…
Read More »
June 27, 2008
Exelixis and GlaxoSmithKline will end their six-year collaboration based on its success, on October 27, 2008, as scheduled. Under the terms of the collaboration, GSK has the right to select two compounds for further development and commercialization.…
Read More »
June 25, 2008
DSM Biologics and Crucell have entered into an agreement with Avid Bioservices to bring Avid into their Vendor Network. Under the terms of the agreement, Avid will be a pre-approved CMO for licensees of the PER.C6 cell line in the western U.S. Avid i…
Read More »
June 24, 2008
WuXi PharmaTech and Covance have entered into a Memorandum of Understanding to create a 50/50 joint venture to provide preclinical contract research services in China. Operations of the proposed joint venture will be located in a 323,450-sq.-ft., pur…
Read More »
June 20, 2008
Sigma-Aldrich has entered into a five-year collaboration to develop optimal cell lines for the production of monoclonal antibodies. Scientists at the University of California, San Francisco will lead the research into antibodies for a variety of canc…
Read More »
June 16, 2008
Mpex Pharmaceuticals and GlaxoSmithKline (GSK) have entered into a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for bacterial diseases. The collaboration provides GSK access to Mpex's efflux pum…
Read More »
June 12, 2008
AMRI will receive a $4 million milestone payment from Bristol-Myers Squibb following BMS's submission of a Clinical Trial Application (CTA) to the Health Products and Food Branch (HPFB), Health Canada for approval to initiate Phase I studies on an AM…
Read More »
June 11, 2008
WuXi PharmaTech has signed a new three-year collaboration agreement with AstraZeneca, expanding a two-year, $14 million collaboration from April 2006 under which WuXi delivered more than 100,000 compounds ahead of schedule. Under the new agreement, W…
Read More »
June 10, 2008
UCB and Otsuka Pharmaceuticals Co. have signed collaboration agreements under which the two companies will co-promote the anti-epileptic drug, Keppra and Cimzia for the treatment of Crohn's Disease, in Japan. They will also co-develop and co-promote…
Read More »
June 3, 2008
Sartorius Stedim Biotech has entered into an agreement with WuXi AppTec, Inc., a subsidiary of WuXi PharmaTech, to work on viral clearance studies. Under this agreement, WuXi AppTec will provide the relevant viruses, materials and methodologies to Sa…
Read More »
May 27, 2008
GVK BIO has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover drug candidates focused on pre-defined discovery targets. GVK BIO will utilize in-house capabilities in discovery chemistry, informatics, biolo…
Read More »
May 27, 2008
Alnylam Pharmaceuticals and Takeda Pharmaceutical Co. Ltd. have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas.
This collaboratio…
Read More »
May 19, 2008
Schering-Plough Corp. has extended its collaboration with MorphoSys AG for one year. The collaboration, announced in May 2006, has a maximum term of five years until 2011 and may be extended by SP after each year. Under the agreement, SP will continu…
Read More »
May 2, 2008
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' lead nicotinic alpha-7 agonist drug candidate, MEM 3454, for neurological and psychiatric disorders. This decision triggers a $6 million milestone payment and…
Read More »
